The FDA has granted Compass Pathways with a rolling review for a New Drug Application (NDA) for its investigational ...
In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license ...
AbbVie received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for ...
Regeneron reached an agreement with the U.S. government to link current and future drug prices to those in other developed ...
EVERSANA’s president discusses the evolving role of the Asembia conference, emerging commercialization trends, and what’s top of mind for pharma leaders this year.
This episode of The Ron Lanton Report explores how geography, policy, and capital are converging to redefine where innovation ...
FDA is formalizing RWD as core evidence, enabling “single pivotal trial plus confirmatory evidence” approaches that may ...
Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...
In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 ...
Eligibility now includes ages 1–7 years with stage 2 T1D, defined by multiple diabetes autoantibodies plus dysglycemia ...
FDA Expands Approval for Dupixent for Young Children with Uncontrolled Chronic Spontaneous Urticaria
Pediatric approval leveraged CupidKids pharmacokinetic bridging and safety assessments, with adverse events consistent across ...
Each April, thousands of leaders across the pharmaceutical and life sciences industry converge in Las Vegas for the Asembia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results